Vertex pays $4.9 Billion for Alpine Immune Science
Post# of 145337
![](/assets/46931549/no_avatar_available_thumb.jpg)
As established in 2022, the igA nephropathy market in the USA was estimated to be about $160 million and projected to be $469.283 million by 2028.
I.gA nephropathy is a rare disease that causes kidney damage when the body's immune system produces antibodies in the kidneys, which leads to INFLAMMATION...
Vertex at theses numbers wouldn't see profit until early 2040...that's a long play.
ohm...are you in the house?
![Like This Post](/images/thumb-up.png)
![Dislike This Post](/images/thumb-down.png)